

Hanfang Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4072614/publications.pdf>

Version: 2024-02-01

16
papers

215
citations

1307366

7
h-index

1058333

14
g-index

16
all docs

16
docs citations

16
times ranked

251
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2021, 21, 149.	1.1	77
2	Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 321-339.	1.4	36
3	Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10-year (2006-2015) retrospective hospitalization summary report-based study. <i>Thoracic Cancer</i> , 2018, 9, 707-717.	0.8	14
4	Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 315-326.	0.7	14
5	Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 149-162.	0.7	12
6	Identification of recurrent <i>BRCA1</i> mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. <i>Cancer Medicine</i> , 2017, 6, 547-554.	1.3	11
7	Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China. <i>Journal of Cancer</i> , 2020, 11, 6612-6622.	1.2	11
8	Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 396-402.	0.7	9
9	First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. <i>Oncology Letters</i> , 2015, 9, 987-993.	0.8	7
10	Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016). <i>Cancer Medicine</i> , 2021, 10, 6089-6098.	1.3	6
11	Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 243-255.	0.7	6
12	The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. <i>Anti-Cancer Drugs</i> , 2022, 33, e635-e643.	0.7	4
13	Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 725-736.	1.1	4
14	Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2014, 26, 550-7.	0.7	3
15	A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1019-1019.	0.8	1
16	Phase II randomized trial of different nab-paclitaxel dose schedule in patients with HER-2 negative recurrent/metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13050-e13050.	0.8	0